Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a prodrug widely used for treating various carcinomas. Gemcitabine exerts its clinical effect by depleting the deoxyribonucleotide pools, and incorporating its triphosphate metabolite (dFdC-TP) into DNA, thereby inhibiting DNA synthesis. This process blocks the cell cycle in the early S phase, eventually resulting in apoptosis. The incorporation of gemcitabine into DNA takes place in competition with the natural nucleoside dCTP. The mechanisms of indirect competition between these cascades for common resources are given with the race for DNA incorporation; in clinical studies dedicated to singling out mechanisms of resistance, ribonucleotide reductase (RR) and deoxycytidine kinase (dCK) and human equilibrative nucleoside transporter1 (hENT1) have been associated to efficacy of gemcitabine with respect to their roles in the synthesis cascades of dFdC-TP and dCTP. However, the direct competition, which manifests itself in terms of inhibitions between these cascades, remains to be quantified. We propose an algorithmic model of gemcitabine mechanism of action, verified with respect to independent experimental data. We performed in silico experiments in different virtual conditions, otherwise difficult in vivo, to evaluate the contribution of the inhibitory mechanisms to gemcitabine efficacy. In agreement with the experimental data, our model indicates that the inhibitions due to the association of dCTP with dCK and the association of gemcitabine diphosphate metabolite (dFdC-DP) with RR play a key role in adjusting the efficacy. While the former tunes the catalysis of the rate-limiting first phosphorylation of dFdC, the latter is responsible for depletion of dCTP pools, thereby contributing to gemcitabine efficacy with a dependency on nucleoside transport efficiency. Our simulations predict the existence of a continuum of non-efficacy to high-efficacy regimes, where the levels of dFdC-TP and dCTP are coupled in a complementary manner, which can explain the resistance to this drug in some patients.
References
[1]
Fryer RA, Barlett B, Galustian C, Dalgleish AG (2011) Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiDTM lenalidomide. Anticancer Research 31: 3747–3756.
[2]
Veltkamp SA, Beijnen JH, Schellens JH (2008) Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. The Oncologist 13: 261–276.
[3]
Funel N, Giovannetti E, Chiaro MD, Mey V, Pollina LE, et al. (2008) Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest 88: 773–784.
[4]
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Annals of oncology official journal of the European Society for Medical Oncology ESMO 17: 7–12.
[5]
Voutsadakis IA (2011) Molecular predictions of gemcitabine response in pancreatic cancer. World Journal of Gastrointestinal Oncology 3: 153–164.
[6]
García-Manteiga J, Molina-Arcas M, Casado FJ, Mazo A, Pastor-Anglada M (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 20,20-diuorodeoxycytidine-induced cytotoxicity. Clinical Cancer Research 9: 5000–5008.
[7]
Veltkamp SA, Pluim D, Eijndhoven MA, Bolijn MJ, Ong FH, et al. (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2,2-diuorodeoxyuridine. Molecular Cancer Therapeutics 7: 2415.
[8]
Regine WF, Winter KA, Abrams RA, Hoffman HSJP, Konski A, et al. (2008) Fluorouracil vs gemcitabine chemotherapy before and after uorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. The journal of the American Medical Association 299: 1019–1026.
[9]
Ren Q, Kao V, Grem JL (1998) Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-uoro-20-deoxyuridine in HT-29 colon cancer cells. Clinical Cancer Research 4: 2811–2818.
[10]
Mackey J, Mani RS, Selner M, Mowles D, Young JD, et al. (1998) Functional nucleoside transporters are required for gemcitabine inux and manifestation of toxicity in cancer cell lines. Cancer Research 58: 4349–57.
[11]
Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, et al. (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12: 807–817.
[12]
Giovannetti E, Tacca MD, Mey V, Funel N, Nannizzi S, et al. (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Research 66: 3928–3935.
[13]
Skrypek N, Duchene B, Hebbar M, Leteurtre E, van Seuningen I, et al. (2012) The muc4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family. Oncogene doi:10.1038/onc.2012.179.
[14]
Sebastiani V, Ricci F, Rubio-Viquiera B, Kulesza P, Yeo CJ, et al. (2006) Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: Relationship to molecular mechanisms of gemcitabine resistance and survival. Clinical Cancer Research 12: 2492–2497.
[15]
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, et al. (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Seminars in Oncology 22: 3–10.
[16]
Kroep JR, Loves WJP, v d Wilt CL, Alvarez E, Talianidis I, et al. (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Molecular Cancer Therapeutics 1: 371–376.
[17]
Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, et al. (2004) An increase in the expression of ribonucleotide reductase in non-small cell lung cancer cell lines large subunit 1 is associated with gemcitabine resistance. Cancer Research 64: 3761–3766.
[18]
Bergman A, Giaccone G, van Moorsel C, Mauritz R, Noordhuis P, et al. (2000) Cross-resistance in the 2,2-diuorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. European Journal of Cancer 36: 1974–1983.
[19]
Nakahira S, Tanno S, Tsujie M, Takahashi Y, Okami J, et al. (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. International Journal of Cancer 120: 1355–1363.
[20]
Dumontet C, Fabianowska-Majewska K, Mantincic D, Bauchu EC, Tigaud I, et al. (1999) Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. British Journal of Haematology 106: 7885.
[21]
Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875–890.
[22]
Eriksson S, Munch-Petersen B, Johansson K, Eklund H (2002) Structure and function of cellular deoxyribonucleoside kinases. Cellular and Molecular Life Sciences 59: 13271346.
[23]
Shahrezaei V, Swain PS (2008) The stochastic nature of biochemical networks. Current Opinion in Biotechnology 19: 369–374.
[24]
Dalchau N, Phillips A, Goldstein LD, Howarth M, Cardelli L, et al. (2011) A peptide filtering relation quantifies MHC class I peptide optimization. PLoS Computational Biology 7: 1–14.
[25]
Romanel A, Jensen LJ, Cardelli L, Csikász-Nagy A (2011) Transcriptional regulation is a major controller of cell cycle transition dynamics. PLoS ONE 7: 1–14.
[26]
Priami C (2009) Algorithmic systems biology. Communications of the ACM 52: 80–88.
[27]
Giovannetti E, Mey V, Danesi R, Mosca I, Tasca MD (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clinical Cancer Research 10: 2936.
[28]
Nurse P (2008) Life, logic and information. Nature 454: 424426.
[29]
Cardelli L, Csikász-Nagy A (2012) The cell cycle switch computes approximate majority. Scientific Reports 2: 1–9.
[30]
Priami C, Ballarini P, Quaglia P (2009) Blenx4bio: Blenx for biologists. In: Proceedings of 7th International Conference of Computational Methods in Systems Biology (CMSB09). .
[31]
Guerriero ML, Dudka A, Underhill-Day N, Heath J, Priami C (2009) Narrative-based computational modelling of the Gp130/JAK/STAT signalling pathway. BMC Systems Biology 3:40: 1–12.
[32]
Kahramano？ullar？ O, Jordán F, Lynch J (2011) Cosbilab graph: the network analysis module of cosbilab. Environmental Modelling and Software 26: 685–687.
[33]
Shao J, Zhou B, Chu B, Yen Y (2006) Ribonucleotide reductase inhibitors and future drug design. Current Cancer Drug Targets 6: 409–431.
[34]
Kim MY, Ives DH (1989) Human deoxycytidine kinase: kinetic mechanism and end-product regulation. Biochemistry 28: 90439047.
Wang J, Lohman GJS, Stubbe J (2007) Enhanced subunit interactions with gemcitabine-5-diphosphate inhibit ribonucleotide reductases. PNAS 104: 14324–14329.
[37]
Artin E, Wang J, Lohman GJS, Yokoyama K, Yu G, et al. (2009) Insight into the mechanism of inactivation of ribonucleotide reductase by gemcitabine 5′-diphosphate in the presence or absence of reductant. Biochemistry 48: 11622–11629.
[38]
Xu YZ, Plunkett W (1992) Modulation of deoxycytidylate deaminase in intact human leukaemia cells. action of 2′,2′-diuorodeoxycytidine. Biochemical Pharmacology 44: 1819–1827.
[39]
van der Graaf PH, Benson N (2011) Systems pharmacology: Bridging systems biology and pharmacokinetics-pharmacodynamics (pkpd) in drug discovery and development. Pharmaceutical Research 28: 1460–1464.
[40]
Cucurull-Sanchez L, Spink KG, Moschos SA (2012) Relevance of systems pharmacology in drug discovery. Drug Discovery Today 17(13–14): 665–670.
[41]
Macheras P, Iliadis A (2006) Modeling in biopharmaceutics, pharmacokinetics, and pharmacodynamics: homogeneous and heterogeneous approaches. Berlin: Springer.
[42]
Tham LS, Wang L, Soo RA, Lee SC, Lee HS, et al. (2008) A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients. Clinical Cancer Research 14(13): 4213–4218.
[43]
Battaglia MA, Parker RS (2011) Pharmacokinetic/pharmacodynamic modelling of intracellular gemcitabine triphosphate accumulation: translating in vitro to in vivo. Systems Biology, IET 5: 34–43.
[44]
Heinemann V, Xu YZ, Chubb S, Sen A, Hertela LW, et al. (1992) Cellular elimination of 2′,2′-diuorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation. Cancer Research 52: 533–539.
[45]
Albano G, Giorno V (2006) A stochastic model of tumor growth. Journal of Theoretical Biology 242: 326–336.
[46]
Lo CF (2009) Stochastic nonlinear Gompertz model of tumor growth. In: Proc. of the World Cong. of Engineering (WCE 2009). Available: http://iaeng.org/publication/WCE2009/WCE？2009_pp1844-1848.pdf. Accessed 2012 Nov 14.
[47]
Lecca P, Kahramano？ullar？ O, Morpurgo D, Priami C, Soo RA (2011) Modelling and estimating dynamics of tumor shrinkage with BlenX and Kinfer. In: 13th International Conference on Computer Modelling and Simulation (UKSim). New York: IEEE. pp. 75–80.
[48]
Beumer JH, Eiseman JL, Parise RA, Joseph E, Covey JM, et al. (2008) Modulation of gemcitabine (2′,2′-diuoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clinical Cancer Research 14: 3529–3535.
[49]
Metharom E, Galettis P, Manners S, Links M (2010) Modulation of gemcitabine accumulation by DNA-damaging agents: mechanisms and specificity in an in vitro model. Anticancer Research 30: 3669–3673.
[50]
Wang S, Zhang H, Malfatti M, de Vere White R, Lara PNJ, et al. (2010) Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chemical Research in Toxicology 23: 1653–1655.
[51]
Danesi R, de Braud F, Fogli S, de Pas TM, di Paolo A, et al. (2003) Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacological Reviews 55: 57–103.
[52]
Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, et al. (2010) Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clinical Pharmacokinetics 49: 549–558.
[53]
Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, et al. (2007) Pharmacokinetics of gemcitabine in japanise cancer patients: the impact of a cytidine deaminase polymorphism. Journal of Clinical Onloclogy 25: 32–42.
[54]
Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, et al. (2010) Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol 66: 611–617.
[55]
Rosell R, Felip E, Majo MTJ, Mendez P, Sanchez-Ronco M, et al. (2004) Gene expression as a predictive marker of outcome in stage iib-iiia-iiib nonsmall cell lung cancer after induction gemcitabinebased chemotherapy followed by resectional surgery. Clin Cancer Res 10: 4215–9.
[56]
Goan YG, Zhou B, Hu E, Mi S, Yen Y (1999) Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-diuorodeoxycytidine in the human kb cancer cell line. Cancer Res 59: 42047.
[57]
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Rna interference targeting the m2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23: 153948.
[58]
Dematté L, Priami C, Romanel A (2008) The BlenX language: A tutorial. SFM, LNCS 5016: 313–365.
[59]
Dematté L, Larcher R, Palmisano A, Priami C, Romanel A (2010) Programming biology in BlenX. Systems Biology for Signaling Networks 1: 777–821.
[60]
Gillespie DT (1977) Exact stochastic simulation of coupled chemical reactions. The Journal of Physical Chemistry 81: 2340–2361.
[61]
Nelder JA, Mead R (1965) A simplex method for function minimization. The Computer Journal 7: 308–313.
[62]
Schmidt H, Jirstrand M (2006) Systems biology toolbox for Matlab: a computational platform for research in systems biology. Bioinformatics 22: 514–515.
[63]
Xie KC, Plunkett W (1996) Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-uoro- b-d-arabinofuranosyl)adenine. Cancer Research 56: 3030–3037.
